查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570846

感染疾病物市場：依產品、病原體、作用機制、給藥途徑和最終用戶 - 2025-2030 年全球預測

Anti-infectives Market by Product (Biologics, Drugs, Vaccines), Pathogen (Bacterial Infections, Fungal Infections, Parasitic Infections), Mechanism Of Action, Route Of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年感染疾病物市值為1,257.8億美元，預計2024年將達到1,314.3億美元，複合年成長率為5.12%，預計2030年將達到1,784.3億美元。

感染疾病物市場包括多種對抗細菌、病毒、真菌和寄生蟲感染疾病的產品。此類別包括抗生素、抗病毒藥物、抗真菌藥物和抗寄生蟲藥。感染疾病物的需求在於它們在醫療保健中的重要作用，它們對於治療感染疾病、預防疾病傳播和降低死亡率至關重要。這些藥物用於醫院、門診診所和居家醫療機構，以滿足人類和動物的需求。該市場面向從兒童到老年人的廣泛人群，並支持製藥和生物技術等眾多行業。

主要市場統計
基準年[2023] 1257.8億美元
預測年份 [2024] 1314.3億美元
預測年份 [2030] 1784.3億美元
複合年成長率（%） 5.12%

推動市場開拓的關鍵因素包括感染疾病流行、抗菌素抗藥性意識的增強以及藥物開發技術的進步。特別是由於多重抗藥性病原體，對新型感染疾病物的需求不斷成長，這帶來了巨大的商機。公司可以透過投資新療法的研發、探索與生物技術公司的合作夥伴關係以及利用人工智慧主導的藥物發現流程來利用這些前景。由於醫療基礎設施的擴大和醫療成本的上升，新興國家也代表著利潤豐厚的市場。

然而，市場面臨阻礙開發新藥步伐的多項挑戰，包括嚴格的監管和不斷上升的研發成本。市場相關人員還必須應對抗菌素抗藥性的複雜挑戰，這需要持續創新和策略投資。最佳的創新途徑包括開發窄頻譜藥物、聯合治療以及根據個人基因譜量身定做的個人化抗感染疾病治療。

總之，感染疾病物市場潛力巨大，但成長需要將策略重點放在克服監管障礙、提高成本效率和促進創新。尋求與學術和研究機構的合作可以提供有價值的見解，並有助於將創新開拓推向市場，幫助企業在這個充滿活力的市場環境中實現永續成長。

市場動態：揭示快速發展的感染疾病物市場的關鍵市場洞察

供需的動態交互作用正在改變感染疾病物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，以及如何減輕消費行為及其對製造成本的影響及其對採購趨勢的影響。

波特五力：駕馭感染疾病物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解感染疾病物市場的外部影響

外部宏觀環境因素在塑造感染疾病物市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解感染疾病物市場競爭狀況

感染疾病物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣感染疾病物市場供應商的績效評估

FPNV定位矩陣是評估感染疾病物市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃感染疾病物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，感染疾病物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告提供了涵蓋關鍵焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧。

2. 市場開拓：辨識新興市場的成長機會，評估現有產業的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢視市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 新興國家醫療基礎設施擴大加速感染疾病物市場成長
      • 嚴格的監管指南，促進有效抗感染藥物的開發和核准
      • 製藥業策略合作與夥伴關係加速抗感染藥物研發
      • 不斷上漲的醫療成本和改善醫療設施的使用正在推動感染疾病物的需求
    • 抑制因素
      • 抗感染藥物市場產品生命週期短、開發成本高，投資收益率低
      • 患者不遵守規定的抗感染治療會導致治療結果不佳和抗藥性增加
    • 機會
      • 基於患者特定因素的標靶抗感染治療的個人化醫療方法的發展
      • 利用人工智慧和機器學習快速辨識新的抗感染化合物
      • 投資先進生物研究以開發下一代抗菌療法
    • 任務
      • 不斷上升的研發成本限制了感染疾病物的創新和新藥發現
      • 市場進入障礙高，阻礙小企業有效競爭
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章感染疾病物市場：依產品

  • 介紹
  • 生技藥品
    • 干擾素
    • 單株抗體
    • 重組蛋白
  • 藥品
    • 靜脈
    • 口服液
    • 錠劑
  • 疫苗
    • 細菌疫苗
    • 病毒疫苗

第7章感染疾病物市場：依病原體分類

  • 介紹
  • 細菌感染疾病
    • 大腸桿菌
    • 金黃色葡萄球菌
  • 黴菌感染疾病
    • 麴菌屬
    • 念珠菌屬
  • 寄生蟲感染疾病
    • 利什曼原蟲症
    • 瘧疾
  • 病毒感染
    • 肝炎
    • HIV

第8章感染疾病物市場：按作用機制

  • 介紹
  • 細胞壁合成抑制劑
  • 核酸合成抑制劑
  • 蛋白質合成抑制劑

第9章感染疾病物市場：依給藥途徑

  • 介紹
  • 靜脈
  • 口服
  • 局部的

第10章感染疾病物市場：依最終用戶分類

  • 介紹
  • 診所
  • 居家醫療
  • 醫院

第11章 美洲感染疾病物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太感染疾病物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲感染疾病物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0031

The Anti-infectives Market was valued at USD 125.78 billion in 2023, expected to reach USD 131.43 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 178.43 billion by 2030.

The anti-infectives market encompasses a broad range of products designed to combat infections caused by bacteria, viruses, fungi, and parasites. This category includes antibiotics, antivirals, antifungals, and antiparasitic agents. The necessity of anti-infectives lies in their critical role in healthcare, as they are essential for treating infections, preventing disease spread, and reducing mortality. These agents find applications in hospitals, outpatient clinics, and home healthcare settings, catering to both human and veterinary needs. The market serves a wide demographic, from pediatric to geriatric populations, and supports numerous industries, including pharmaceuticals and biotechnology.

KEY MARKET STATISTICS
Base Year [2023] USD 125.78 billion
Estimated Year [2024] USD 131.43 billion
Forecast Year [2030] USD 178.43 billion
CAGR (%) 5.12%

Market growth is primarily driven by factors such as the increasing prevalence of infectious diseases, growing awareness of antimicrobial resistance, and advances in drug development technologies. The rising need for new classes of anti-infectives, especially due to multidrug-resistant pathogens, presents significant opportunities. Companies can capitalize on these prospects by investing in R&D for novel therapeutics, exploring partnerships with biotechnology firms, and leveraging AI-driven drug discovery processes. Emerging economies also present lucrative markets due to their expanding healthcare infrastructure and rising healthcare expenditure.

However, the market faces several challenges, including stringent regulatory mandates and the high cost of R&D, which can hinder the pace of new drug development. Market players must also navigate the complexities of antimicrobial resistance, which requires continuous innovation and strategic investment. The best avenues for innovation include development of narrow-spectrum agents, combination therapies, and personalized anti-infective treatments tailored to individual genetic profiles.

In conclusion, while the anti-infectives market holds expansive potential, growth demands strategic focus on overcoming regulatory hurdles, improving cost efficiency, and fostering innovation. Pursuing collaborations with academic and research institutions can provide valuable insights and boost the development of groundbreaking solutions, positioning companies for sustainable growth in this dynamic market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-infectives Market

The Anti-infectives Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of healthcare infrastructure in emerging economies fueling the anti-infectives market growth
    • Stringent regulatory guidelines promoting the development and approval of effective anti-infective medications
    • The pharmaceutical industry's strategic collaborations and partnerships to boost anti-infective drug discovery
    • Increasing healthcare expenditure and better access to medical facilities driving demand for anti-infectives
  • Market Restraints
    • Lower return on investment due to short product lifecycles and high cost of development in anti-infective market
    • Patient non-adherence to prescribed anti-infective regimens leading to suboptimal treatment outcomes and increased resistance
  • Market Opportunities
    • Growth of personalized medicine approaches for targeted anti-infective treatments based on patient-specific factors
    • Leveraging artificial intelligence and machine learning for rapid identification of novel anti-infective compounds
    • Investing in advanced biotechnological research for development of next-generation anti-microbial therapies
  • Market Challenges
    • Escalating research and development costs limiting innovation and new drug discoveries in anti-infectives
    • High market entry barriers preventing small and medium-sized enterprises from competing effectively

Porter's Five Forces: A Strategic Tool for Navigating the Anti-infectives Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-infectives Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-infectives Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-infectives Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-infectives Market

A detailed market share analysis in the Anti-infectives Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-infectives Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-infectives Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-infectives Market

A strategic analysis of the Anti-infectives Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-infectives Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Anti-infectives Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Biologics, Drugs, and Vaccines. The Biologics is further studied across Interferons, Monoclonal Antibodies, and Recombinant Proteins. The Drugs is further studied across Intravenous, Oral Liquids, and Tablets. The Vaccines is further studied across Bacterial Vaccines and Viral Vaccines.
  • Based on Pathogen, market is studied across Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections. The Bacterial Infections is further studied across Escherichia Coli and Staphylococcus Aureus. The Fungal Infections is further studied across Aspergillus and Candida. The Parasitic Infections is further studied across Leishmaniasis and Malaria. The Viral Infections is further studied across Hepatitis and HIV.
  • Based on Mechanism Of Action, market is studied across Cell Wall Synthesis Inhibitors, Nucleic Acid Synthesis Inhibitors, and Protein Synthesis Inhibitors.
  • Based on Route Of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on End User, market is studied across Clinics, Homecare, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of healthcare infrastructure in emerging economies fueling the anti-infectives market growth
      • 5.1.1.2. Stringent regulatory guidelines promoting the development and approval of effective anti-infective medications
      • 5.1.1.3. The pharmaceutical industry's strategic collaborations and partnerships to boost anti-infective drug discovery
      • 5.1.1.4. Increasing healthcare expenditure and better access to medical facilities driving demand for anti-infectives
    • 5.1.2. Restraints
      • 5.1.2.1. Lower return on investment due to short product lifecycles and high cost of development in anti-infective market
      • 5.1.2.2. Patient non-adherence to prescribed anti-infective regimens leading to suboptimal treatment outcomes and increased resistance
    • 5.1.3. Opportunities
      • 5.1.3.1. Growth of personalized medicine approaches for targeted anti-infective treatments based on patient-specific factors
      • 5.1.3.2. Leveraging artificial intelligence and machine learning for rapid identification of novel anti-infective compounds
      • 5.1.3.3. Investing in advanced biotechnological research for development of next-generation anti-microbial therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Escalating research and development costs limiting innovation and new drug discoveries in anti-infectives
      • 5.1.4.2. High market entry barriers preventing small and medium-sized enterprises from competing effectively
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-infectives Market, by Product

  • 6.1. Introduction
  • 6.2. Biologics
    • 6.2.1. Interferons
    • 6.2.2. Monoclonal Antibodies
    • 6.2.3. Recombinant Proteins
  • 6.3. Drugs
    • 6.3.1. Intravenous
    • 6.3.2. Oral Liquids
    • 6.3.3. Tablets
  • 6.4. Vaccines
    • 6.4.1. Bacterial Vaccines
    • 6.4.2. Viral Vaccines

7. Anti-infectives Market, by Pathogen

  • 7.1. Introduction
  • 7.2. Bacterial Infections
    • 7.2.1. Escherichia Coli
    • 7.2.2. Staphylococcus Aureus
  • 7.3. Fungal Infections
    • 7.3.1. Aspergillus
    • 7.3.2. Candida
  • 7.4. Parasitic Infections
    • 7.4.1. Leishmaniasis
    • 7.4.2. Malaria
  • 7.5. Viral Infections
    • 7.5.1. Hepatitis
    • 7.5.2. HIV

8. Anti-infectives Market, by Mechanism Of Action

  • 8.1. Introduction
  • 8.2. Cell Wall Synthesis Inhibitors
  • 8.3. Nucleic Acid Synthesis Inhibitors
  • 8.4. Protein Synthesis Inhibitors

9. Anti-infectives Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Topical

10. Anti-infectives Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Homecare
  • 10.4. Hospitals

11. Americas Anti-infectives Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Anti-infectives Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Anti-infectives Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Bristol-Myers Squibb Company
  • 8. Cubist Pharmaceuticals, Inc.
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche AG
  • 11. Gilead Sciences, Inc.
  • 12. GlaxoSmithKline plc
  • 13. Johnson & Johnson
  • 14. Merck & Co., Inc.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.
  • 18. Shionogi & Co., Ltd.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. ANTI-INFECTIVES MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-INFECTIVES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTI-INFECTIVES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTI-INFECTIVES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-INFECTIVES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-INFECTIVES MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ASPERGILLUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CANDIDA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MALARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEIC ACID SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 247. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 259. THAILAND ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 260. THAILAND ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 271. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 272. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 295. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 296. DENMARK ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 297. DENMARK ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 307. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 308. EGYPT ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 309. EGYPT ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 310. EGYPT ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 320. FINLAND ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 321. FINLAND ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 322. FINLAND ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 323. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 331. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 332. FRANCE ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 333. FRANCE ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 334. FRANCE ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 335. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 336. FRANCE ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 342. FRANCE ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 343. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 344. GERMANY ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 345. GERMANY ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 346. GERMANY ANTI-INFECTIVES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 347. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 348. GERMANY ANTI-INFECTIVES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 349. GERMANY ANTI-INFECTIVES MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 350. GERMANY ANTI-INFECTIVES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 351. GERMANY ANTI-INFECTIVES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 352. GERMANY ANTI-INFECTIVES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 353. GERMANY ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 354. GERMANY ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 355. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 356. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 357. ISRAEL ANTI-INFECTIVES MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 358. ISRAEL